<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE nitf SYSTEM "http://www.nitf.org/IPTC/NITF/3.3/specification/dtd/nitf-3-3.dtd">
<nitf change.date="June 10, 2005" change.time="19:30" version="-//IPTC//DTD NITF 3.3//EN">
  <head>
    <title>DIABETES DRUG APPROVED</title>
    <meta content="MB013002" name="slug"/>
    <meta content="6" name="publication_day_of_month"/>
    <meta content="10" name="publication_month"/>
    <meta content="2000" name="publication_year"/>
    <meta content="Friday" name="publication_day_of_week"/>
    <meta content="Business/Financial Desk" name="dsk"/>
    <meta content="1" name="print_page_number"/>
    <meta content="W" name="print_section"/>
    <meta content="3" name="print_column"/>
    <meta content="Health; Business" name="online_sections"/>
    <docdata>
      <doc-id id-string="1236556"/>
      <doc.copyright holder="The New York Times" year="2000"/>
      <series series.name="WORLD BUSINESS BRIEFING: EUROPE"/>
      <identified-content>
        <classifier class="indexing_service" type="descriptor">Diabetes</classifier>
        <classifier class="indexing_service" type="descriptor">Regulation and Deregulation of Industry</classifier>
        <classifier class="indexing_service" type="descriptor">Drugs (Pharmaceuticals)</classifier>
        <classifier class="indexing_service" type="descriptor">Starlix (Drug)</classifier>
        <classifier class="indexing_service" type="descriptor">Glucophage (Drug)</classifier>
        <location class="indexing_service">Switzerland</location>
        <org class="indexing_service">Novartis Ag</org>
        <org class="indexing_service">Merck &amp; Co Inc</org>
        <person class="indexing_service">Olson, Elizabeth</person>
        <classifier class="online_producer" type="taxonomic_classifier">Top/News/Business</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/News/Business/World Business</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/News/Health</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/Classifieds/Job Market/Job Categories/Pharmaceutical, Biotechnology and Science</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/Features/Travel/Guides/Destinations/Europe</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/Features/Travel/Guides/Destinations/Europe/Switzerland</classifier>
        <classifier class="online_producer" type="general_descriptor">Regulation and Deregulation of Industry</classifier>
        <classifier class="online_producer" type="general_descriptor">Diabetes</classifier>
        <classifier class="online_producer" type="general_descriptor">Drugs (Pharmaceuticals)</classifier>
        <classifier class="online_producer" type="general_descriptor">Diseases and Conditions</classifier>
        <classifier class="online_producer" type="general_descriptor">Medicine and Health</classifier>
      </identified-content>
    </docdata>
    <pubdata date.publication="20001006T000000" ex-ref="http://query.nytimes.com/gst/fullpage.html?res=9B03E0DD143CF935A35753C1A9669C8B63" item-length="112" name="The New York Times" unit-of-measure="word"/>
  </head>
  <body>
    <body.head>
      <hedline>
        <hl1>DIABETES DRUG APPROVED</hl1>
      </hedline>
      <byline class="print_byline">By Elizabeth Olson</byline>
      <byline class="normalized_byline">Olson, Elizabeth</byline>
      <abstract>
        <p>Novartis AG of Switzerland and Merck &amp; Co of Germany win their first regulatory approval to sell diabetes drug, Starlix; Swiss regulators approve drug for use alone or with Merck's Glucophage; Novartis will now seek approval from regulators in US to begin marketing Starlix in first quarter of 2001 (S)</p>
      </abstract>
    </body.head>
    <body.content>
      <block class="lead_paragraph">
        <p>Novartis A.G. of Switzerland and Merck of Germany have won their first regulatory approval to sell the diabetes medicine, Starlix. Swiss regulators have approved the drug for use alone or with Merck's Glucophage, the world's best-selling noninsulin diabetes treatment. Novartis, Europe's third- largest drug maker, will now seek approval from regulators in the United States to begin marketing Starlix in the first quarter of 2001.</p>
        <p>Elizabeth Olson (NYT)</p>
      </block>
      <block class="full_text">
        <p>Novartis A.G. of Switzerland and Merck of Germany have won their first regulatory approval to sell the diabetes medicine, Starlix. Swiss regulators have approved the drug for use alone or with Merck's Glucophage, the world's best-selling noninsulin diabetes treatment. Novartis, Europe's third- largest drug maker, will now seek approval from regulators in the United States to begin marketing Starlix in the first quarter of 2001.</p>
        <p>Elizabeth Olson (NYT)</p>
        <p>WORLD BUSINESS BRIEFING: EUROPE</p>
      </block>
    </body.content>
  </body>
</nitf>
